[go: up one dir, main page]

BRPI0410860A - cadeias leve e pesada de imunoglobulina humanizada, imunoglobulina humanizada, anticorpo humanizado, imunoglobulina quimérica, composição farmacêutica, polipeptìdeo isolado, variante de um polipeptìdeo, molécula de ácido nucleico isolada, vetor, célula hospedeira, animal transgênico, uso da seqüência de região variável, kit para formar imagem, composição terapêutica, e, métodos para prevenir ou tratar uma doença amiloidogênica e mal de alzheimer em um paciente, para produzir um anticorpo ou fragmento do mesmo, para identificar resìduos passiveis de substituição, para formar imagem de depósitos de amilóides no cérebro de um paciente, para reduzir carga de placa em um sujeito, para reduzir carga neurìtica em um sujeito, e, para reduzir carga de peptìdeo beta amilóide e distrofia neurìtica em um mamìfero - Google Patents

cadeias leve e pesada de imunoglobulina humanizada, imunoglobulina humanizada, anticorpo humanizado, imunoglobulina quimérica, composição farmacêutica, polipeptìdeo isolado, variante de um polipeptìdeo, molécula de ácido nucleico isolada, vetor, célula hospedeira, animal transgênico, uso da seqüência de região variável, kit para formar imagem, composição terapêutica, e, métodos para prevenir ou tratar uma doença amiloidogênica e mal de alzheimer em um paciente, para produzir um anticorpo ou fragmento do mesmo, para identificar resìduos passiveis de substituição, para formar imagem de depósitos de amilóides no cérebro de um paciente, para reduzir carga de placa em um sujeito, para reduzir carga neurìtica em um sujeito, e, para reduzir carga de peptìdeo beta amilóide e distrofia neurìtica em um mamìfero

Info

Publication number
BRPI0410860A
BRPI0410860A BRPI0410860-4A BRPI0410860A BRPI0410860A BR PI0410860 A BRPI0410860 A BR PI0410860A BR PI0410860 A BRPI0410860 A BR PI0410860A BR PI0410860 A BRPI0410860 A BR PI0410860A
Authority
BR
Brazil
Prior art keywords
reduce
patient
subject
humanized
neuritically
Prior art date
Application number
BRPI0410860-4A
Other languages
English (en)
Inventor
Guriq Basi
Jose W Saldanha
Frederique Bard
Original Assignee
Neuralab Ltd
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neuralab Ltd, Wyeth Corp filed Critical Neuralab Ltd
Publication of BRPI0410860A publication Critical patent/BRPI0410860A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

"CADEIAS LEVE E PESADA DE IMUNOGLOBULINA HUMANIZADA, IMUNOGLOBULINA HUMANIZADA, ANTICORPO HUMANIZADO, IMUNOGLOBULINA QUIMéRICA, COMPOSIçãO FARMACêUTICA, POLIPEPTìDEO ISOLADO, VARIANTE DE UM POLIPEPTìDEO, MOLéCULA DE áCIDO NUCLEICO ISOLADA, VETOR, CéLULA HOSPEDEIRA, ANIMAL TRANSGêNICO, USO DA SEQüêNCIA DE REGIãO VARIáVEL, KIT PARA FORMAR IMAGEM, COMPOSIçãO TERAPêUTICA, E, MéTODOS PARA PREVENIR OU TRATAR UMA DOENçA AMILOIDOGêNICA E MAL DE ALZHEIMER EM UM PACIENTE, PARA PRODUZIR UM ANTICORPO OU FRAGMENTO DO MESMO, PARA IDENTIFICAR RESìDUOS PASSìVEIS DE SUBSTITUIçãO, PARA FORMAR IMAGEM DE DEPóSITOS DE AMILóIDES NO CéREBRO DE UM PACIENTE, PARA REDUZIR CARGA DE PLACA EM UM SUJEITO, PARA REDUZIR CARGA NEURìTICA EM UM SUJEITO, E, PARA REDUZIR CARGA DE PEPTìDEO BETA AMILóIDE E DISTROFIA NEURìTICA EM UM MAMìFERO". A invenção proporciona agentes e métodos aperfeiçoados para tratamento de doenças associadas com depósitos amilóides de A<225> no cérebro de um paciente. Agentes preferidos incluem anticorpos, por exemplo, anticorpos humanizados.
BRPI0410860-4A 2003-05-30 2004-06-01 cadeias leve e pesada de imunoglobulina humanizada, imunoglobulina humanizada, anticorpo humanizado, imunoglobulina quimérica, composição farmacêutica, polipeptìdeo isolado, variante de um polipeptìdeo, molécula de ácido nucleico isolada, vetor, célula hospedeira, animal transgênico, uso da seqüência de região variável, kit para formar imagem, composição terapêutica, e, métodos para prevenir ou tratar uma doença amiloidogênica e mal de alzheimer em um paciente, para produzir um anticorpo ou fragmento do mesmo, para identificar resìduos passiveis de substituição, para formar imagem de depósitos de amilóides no cérebro de um paciente, para reduzir carga de placa em um sujeito, para reduzir carga neurìtica em um sujeito, e, para reduzir carga de peptìdeo beta amilóide e distrofia neurìtica em um mamìfero BRPI0410860A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47465403P 2003-05-30 2003-05-30
PCT/US2004/017514 WO2004108895A2 (en) 2003-05-30 2004-06-01 Humanized antibodies that recognize beta amyloid peptide

Publications (1)

Publication Number Publication Date
BRPI0410860A true BRPI0410860A (pt) 2006-07-04

Family

ID=33511618

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0410860-4A BRPI0410860A (pt) 2003-05-30 2004-06-01 cadeias leve e pesada de imunoglobulina humanizada, imunoglobulina humanizada, anticorpo humanizado, imunoglobulina quimérica, composição farmacêutica, polipeptìdeo isolado, variante de um polipeptìdeo, molécula de ácido nucleico isolada, vetor, célula hospedeira, animal transgênico, uso da seqüência de região variável, kit para formar imagem, composição terapêutica, e, métodos para prevenir ou tratar uma doença amiloidogênica e mal de alzheimer em um paciente, para produzir um anticorpo ou fragmento do mesmo, para identificar resìduos passiveis de substituição, para formar imagem de depósitos de amilóides no cérebro de um paciente, para reduzir carga de placa em um sujeito, para reduzir carga neurìtica em um sujeito, e, para reduzir carga de peptìdeo beta amilóide e distrofia neurìtica em um mamìfero

Country Status (30)

Country Link
US (1) US7871615B2 (pt)
EP (1) EP1636268B8 (pt)
JP (1) JP4908203B2 (pt)
KR (2) KR101152583B1 (pt)
CN (1) CN1798766B (pt)
AR (1) AR044580A1 (pt)
AT (1) ATE545656T1 (pt)
AU (1) AU2004245989B2 (pt)
BR (1) BRPI0410860A (pt)
CA (1) CA2525975C (pt)
CO (1) CO5660296A2 (pt)
CR (1) CR8095A (pt)
DK (1) DK1636268T3 (pt)
EA (1) EA012407B1 (pt)
EC (1) ECSP056263A (pt)
ES (1) ES2382547T3 (pt)
IL (1) IL171877A (pt)
MX (1) MXPA05012718A (pt)
MY (1) MY176959A (pt)
NO (1) NO20055415L (pt)
NZ (1) NZ544324A (pt)
PE (1) PE20050627A1 (pt)
PL (1) PL1636268T3 (pt)
PT (1) PT1636268E (pt)
SI (1) SI1636268T1 (pt)
TW (2) TWI306458B (pt)
UA (1) UA90846C2 (pt)
UY (1) UY28337A1 (pt)
WO (1) WO2004108895A2 (pt)
ZA (1) ZA200509585B (pt)

Families Citing this family (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7588766B1 (en) 2000-05-26 2009-09-15 Elan Pharma International Limited Treatment of amyloidogenic disease
US7964192B1 (en) * 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US6787523B1 (en) * 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6761888B1 (en) 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
TWI255272B (en) * 2000-12-06 2006-05-21 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US7658924B2 (en) * 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
WO2004069182A2 (en) * 2003-02-01 2004-08-19 Neuralab Limited Active immunization to generate antibodies to soluble a-beta
TWI306458B (en) 2003-05-30 2009-02-21 Elan Pharma Int Ltd Humanized antibodies that recognize beta amyloid peptide
EP1828251B1 (en) * 2004-10-05 2012-09-26 Janssen Alzheimer Immunotherapy Methods and compositions for improving recombinant protein production
ES2641815T3 (es) 2004-10-29 2017-11-14 Eisai R&D Management Co., Ltd. Tratamiento para enfermedades inflamatorias
CA2590337C (en) * 2004-12-15 2017-07-11 Neuralab Limited Humanized amyloid beta antibodies for use in improving cognition
US7625560B2 (en) * 2004-12-15 2009-12-01 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
AR051800A1 (es) * 2004-12-15 2007-02-07 Wyeth Corp Anticuerpos a beta usados en mejorar la cognicion
EP1841455A1 (en) 2005-01-24 2007-10-10 Amgen Inc. Humanized anti-amyloid antibody
GT200600031A (es) 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
CA2595380A1 (en) * 2005-01-28 2006-08-03 Wyeth Stabilized liquid polypeptide formulations
ES2318918B1 (es) * 2005-04-01 2010-02-16 Biotherapix Molecular Medicines, S.L.U. Anticuerpos humanos con capacidad de union al peptido beta-amiloide y sus aplicaciones.
UY29504A1 (es) 2005-04-29 2006-10-31 Rinat Neuroscience Corp Anticuerpos dirigidos contra el péptido amiloide beta y métodos que utilizan los mismos.
KR101247836B1 (ko) 2005-06-17 2013-03-28 와이어쓰 엘엘씨 항 ａ 베타 항체의 정제 방법
JP5289963B2 (ja) * 2005-10-21 2013-09-11 メルク・シャープ・アンド・ドーム・コーポレーション 抗ａｄｄｌモノクローナル抗体およびその使用
DK1954718T3 (en) 2005-11-30 2014-12-15 Abbvie Inc Anti-A-globulomer antibodies antigenbindingsgrupper thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods for producing said antibodies,
CN101506236B (zh) 2005-11-30 2012-12-12 雅培制药有限公司 抗淀粉样β蛋白的单克隆抗体及其用途
MX358175B (es) * 2005-12-12 2018-08-08 Ac Immune Sa Anticuerpos monoclonales especificos 1-42 beta con propiedades terapeuticas.
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
WO2009017467A1 (en) * 2007-07-27 2009-02-05 Elan Pharma International Limited Treatment of amyloidogenic diseases
RU2498999C2 (ru) 2006-07-14 2013-11-20 Ац Иммуне Са Гуманизированное антитело к амилоиду бета
JP2010506839A (ja) * 2006-10-12 2010-03-04 ワイス エルエルシー 乳光の低減を伴う方法および組成物
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
AU2008203703C1 (en) 2007-01-05 2014-04-03 University Of Zurich Method of providing disease-specific binding molecules and targets
HRP20140049T1 (hr) 2007-01-05 2014-02-28 University Of Zürich Anti beta-amiloid antitijela i njihova upotreba
US20100311767A1 (en) 2007-02-27 2010-12-09 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
MX2009009234A (es) 2007-03-01 2009-12-01 Probiodrug Ag Uso nuevo de inhibidores de ciclasa de glutaminilo.
US8003097B2 (en) * 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
DK2142514T3 (da) 2007-04-18 2015-03-23 Probiodrug Ag Thioureaderivater som glutaminylcyclase-inhibitorer
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
SG182192A1 (en) * 2007-06-12 2012-07-30 Ac Immune Sa Humanized antibodies to amyloid beta
US8048420B2 (en) * 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
DK2158315T3 (en) 2007-06-25 2016-06-06 Esbatech Alcon Biomed Res Unit Methods of modifying antibodies and modified antibodies with improved functional properties
EP2020602A1 (en) * 2007-08-02 2009-02-04 Araclon Biotech High sensitivty immunoassays and kits for the determination of peptides and proteins of biological interest
DK2238166T3 (da) 2007-10-05 2014-01-27 Ac Immune Sa Anvendelse af et anti-amyloid-beta-antistof ved øjensygdomme
RU2542967C2 (ru) * 2007-10-05 2015-02-27 Дженентек, Инк. Применение антитела против амилоида бета при глазных заболеваниях
AU2008311365B2 (en) * 2007-10-05 2015-03-12 Ac Immune S.A. Humanized antibody
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
CA2709354C (en) 2007-12-21 2014-06-17 Amgen Inc. Anti-amyloid antibodies and uses thereof
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
EP2321348A2 (en) * 2008-07-09 2011-05-18 University of Zürich Method of promoting neurogenesis
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
WO2010056893A1 (en) * 2008-11-13 2010-05-20 Imclone Llc Humanization and affinity-optimization of antibodies
HRP20150831T1 (hr) 2008-12-19 2015-10-09 Biogen International Neuroscience Gmbh Humana anti-alfa- sinuklein auto-protutijela
US8614297B2 (en) 2008-12-22 2013-12-24 Hoffmann-La Roche Inc. Anti-idiotype antibody against an antibody against the amyloid β peptide
CN101463083B (zh) * 2009-01-16 2011-12-28 清华大学 与A-beta寡聚体特异性结合的基因工程单克隆抗体
CN101463085B (zh) * 2009-01-16 2011-09-14 清华大学 与A-beta寡聚体特异性结合的基因工程单克隆抗体
CN101463082B (zh) * 2009-01-16 2011-12-28 清华大学 与A-beta寡聚体特异性结合的基因工程单克隆抗体
WO2011029920A1 (en) 2009-09-11 2011-03-17 Probiodrug Ag Heterocylcic derivatives as inhibitors of glutaminyl cyclase
JO3437B1 (ar) * 2009-10-30 2019-10-20 Esai R & D Man Co Ltd أجسام مضادة محسنة مضادة للفراكتالكين البشري واستخداماتها
US8765432B2 (en) 2009-12-18 2014-07-01 Oligasis, Llc Targeted drug phosphorylcholine polymer conjugates
WO2011107530A2 (en) 2010-03-03 2011-09-09 Probiodrug Ag Novel inhibitors
EP2542579A1 (en) 2010-03-03 2013-01-09 Boehringer Ingelheim International GmbH Biparatopic abeta binding polypeptides
SG183229A1 (en) 2010-03-10 2012-09-27 Probiodrug Ag Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5)
MX360403B (es) * 2010-04-15 2018-10-31 Abbvie Inc Proteinas de union a amiloide beta.
US8541596B2 (en) 2010-04-21 2013-09-24 Probiodrug Ag Inhibitors
CA2806909C (en) 2010-07-30 2019-12-17 Ac Immune S.A. Safe and functional humanized antibodies
JP6147665B2 (ja) 2010-08-14 2017-06-14 アッヴィ・インコーポレイテッド アミロイドベータ結合タンパク質
EP2686313B1 (en) 2011-03-16 2016-02-03 Probiodrug AG Benzimidazole derivatives as inhibitors of glutaminyl cyclase
BR112013033258B1 (pt) 2011-06-23 2022-09-20 University Of Zurich Anticorpo isolado ou fragmento de ligação ao antígeno do mesmo que se liga a alfasinucleína, composição e seus usos
JP2012050437A (ja) * 2011-09-12 2012-03-15 Janssen Alzheimer Immunotherapy ベータアミロイドペプチドを認識するヒト化抗体
PE20151926A1 (es) 2013-05-20 2016-01-07 Genentech Inc Anticuerpos de receptores de antitransferrina y metodos de uso
US9587032B2 (en) 2013-06-12 2017-03-07 The Board Of Trustees Of The Leland Stanford Junior University IgE antibodies for the inhibition of tumor metastasis
HUE052447T2 (hu) 2013-09-08 2021-04-28 Kodiak Sciences Inc A VIII. tényezõs zwitterionos polimer konjugációk
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
JP6849590B2 (ja) 2014-10-17 2021-03-24 コディアック サイエンシーズ インコーポレイテッドＫｏｄｉａｋ Ｓｃｉｅｎｃｅｓ Ｉｎｃ． ブチリルコリンエステラーゼ両性イオン性ポリマーコンジュゲート
US10508151B2 (en) 2014-11-19 2019-12-17 Genentech, Inc. Anti-transferrin receptor antibodies and methods of use
US11008403B2 (en) 2014-11-19 2021-05-18 Genentech, Inc. Anti-transferrin receptor / anti-BACE1 multispecific antibodies and methods of use
MA41115A (fr) 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer
MX2017007491A (es) 2014-12-10 2018-05-04 Genentech Inc Anticuerpos del receptor de la barrera hematoencefálica y métodos para su uso.
EP3374383A4 (en) 2015-11-09 2019-05-15 The University Of British Columbia AMYLOID BETA EPITOPES AND ANTIBODIES
JP7065516B2 (ja) 2015-11-09 2022-05-12 ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア アミロイドベータのｎ末端エピトープおよびそれに対する立体配座選択的抗体
CA3004494A1 (en) 2015-11-09 2017-05-18 The University Of British Columiba Epitopes in amyloid beta mid-region and conformationally-selective antibodies thereto
JP2016047839A (ja) * 2015-11-24 2016-04-07 ヤンセン・サイエンシズ・アイルランド・ユーシー アミロイド原性疾患の処置
JP7088454B2 (ja) 2015-12-30 2022-06-21 コディアック サイエンシーズ インコーポレイテッド 抗体および抗体複合体
CN116333108A (zh) 2016-07-18 2023-06-27 英属哥伦比亚大学 淀粉样蛋白β的抗体
US20180125920A1 (en) 2016-11-09 2018-05-10 The University Of British Columbia Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions
US12286469B2 (en) 2017-07-18 2025-04-29 The University Of British Columbia Humanized antibodies binding to amyloid-beta (A-beta)
WO2019023247A1 (en) 2017-07-25 2019-01-31 Immutics, Inc. TREATMENT OF CANCER BY BLOCKING THE INTERACTION OF TIM-3 AND ITS LIGAND
RS64289B1 (sr) 2017-08-22 2023-07-31 Biogen Ma Inc Farmaceutske kompozicije koje sadrže anti-amiloid beta antitela
DK3461819T3 (da) 2017-09-29 2020-08-10 Probiodrug Ag Inhibitorer af glutaminylcyklase
EP3758737A4 (en) 2018-03-02 2022-10-12 Kodiak Sciences Inc. IL-6 ANTIBODIES AND FUSION CONSTRUCTS AND CONJUGATES THEREOF
BR112020027055A2 (pt) 2018-07-17 2021-04-06 Jiangsu Hengrui Medicine Co., Ltd. Anticorpo anti-abeta, fragmento de ligação ao antígeno do mesmo e aplicação dos mesmos
JP7611149B2 (ja) 2018-10-04 2025-01-09 ユニバーシティ オブ ロチェスター 血漿浸透圧を操作することによるグリンパティック送達の改善
AR117453A1 (es) 2018-12-20 2021-08-04 Genentech Inc Fc de anticuerpos modificados y métodos para utilizarlas
CN111518206B (zh) * 2019-02-01 2022-03-29 长春金赛药业有限责任公司 人源化抗Aβ单克隆抗体及其应用
WO2021072265A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
JP2023528797A (ja) 2020-05-26 2023-07-06 トゥルーバインディング，インコーポレイテッド ガレクチン－３を遮断することにより炎症性疾患を処置する方法
MX2023000949A (es) 2020-07-23 2023-02-22 Othair Prothena Ltd Anticuerpos anti-beta-amiloide (abeta).
TW202300517A (zh) 2021-03-12 2023-01-01 美商美國禮來大藥廠 抗類澱粉β抗體及其用途
WO2022251048A1 (en) 2021-05-24 2022-12-01 Eli Lilly And Company Anti-amyloid beta antibodies and uses thereof
WO2024086796A1 (en) 2022-10-20 2024-04-25 Alector Llc Anti-ms4a4a antibodies with amyloid-beta therapies
WO2025044931A1 (zh) * 2023-08-25 2025-03-06 康诺亚生物医药科技（成都）有限公司 阿尔茨海默病治疗剂的开发和应用

Family Cites Families (280)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5208036A (en) 1985-01-07 1993-05-04 Syntex (U.S.A.) Inc. N-(ω, (ω-1)-dialkyloxy)- and N-(ω, (ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4666829A (en) 1985-05-15 1987-05-19 University Of California Polypeptide marker for Alzheimer's disease and its use for diagnosis
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US4713366A (en) 1985-12-04 1987-12-15 The Ohio State University Research Foundation Antigenic modification of polypeptides
US5096706A (en) 1986-03-25 1992-03-17 National Research Development Corporation Antigen-based treatment for adiposity
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US6548640B1 (en) * 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5278049A (en) 1986-06-03 1994-01-11 Incyte Pharmaceuticals, Inc. Recombinant molecule encoding human protease nexin
US5231170A (en) 1986-08-27 1993-07-27 Paul Averback Antibodies to dense microspheres
US5187153A (en) 1986-11-17 1993-02-16 Scios Nova Inc. Methods of treatment using Alzheimer's amyloid polypeptide derivatives
US5220013A (en) 1986-11-17 1993-06-15 Scios Nova Inc. DNA sequence useful for the detection of Alzheimer's disease
US4879213A (en) 1986-12-05 1989-11-07 Scripps Clinic And Research Foundation Synthetic polypeptides and antibodies related to Epstein-Barr virus early antigen-diffuse
US4912206A (en) 1987-02-26 1990-03-27 The United States Of America As Represented By The Department Of Health And Human Services CDNA clone encoding brain amyloid of alzheimer's disease
DE3883899T3 (de) * 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US5583112A (en) 1987-05-29 1996-12-10 Cambridge Biotech Corporation Saponin-antigen conjugates and the use thereof
US5245015A (en) * 1991-04-26 1993-09-14 Tanox Biosystems, Inc. Monoclonal antibodies which neutralize HIV-1 through reaction with a conformational epitope in vitro
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US5571500A (en) 1987-06-24 1996-11-05 Autoimmune, Inc. Treatment of autoimmune diseases through administration by inhalation of autoantigens
US5869054A (en) 1987-06-24 1999-02-09 Autoimmune Inc. Treatment of multiple sclerosis by oral administration of autoantigens
US5849298A (en) 1987-06-24 1998-12-15 Autoimmune Inc. Treatment of multiple sclerosis by oral administration of bovine myelin
US5645820A (en) 1987-06-24 1997-07-08 Autoimmune, Inc. Treatment of autoimmune diseases by aerosol administration of autoantigens
DE3856566T2 (de) 1987-06-24 2004-06-24 Brigham And Women's Hospital, Boston Behandlung von Autoimmun-Erkrankungen durch orale Verabreichung von Autoantigenen
US5641474A (en) 1987-06-24 1997-06-24 Autoimmune, Inc. Prevention of autoimmune diseases by aerosol administration of autoantigens
US5571499A (en) 1987-06-24 1996-11-05 Autoimmune, Inc. Treatment of autoimmune diseases by aerosol administration of autoantigens
US5004697A (en) 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
CA1339014C (en) 1987-10-08 1997-03-25 Ronald E. Majocha Antibodies to a4 amyloid peptide
US5231000A (en) 1987-10-08 1993-07-27 The Mclean Hospital Antibodies to A4 amyloid peptide
EP0382781B1 (en) 1987-10-23 1993-09-29 Genetics Institute, Inc. Composition for treating cancers characterized by over-expression of the c-fms proto-oncogene
US5089603A (en) * 1989-06-21 1992-02-18 Tanox Biosystems, Inc. Antigenic epitopes present on membrane-bound but not secreted iga
AU3056289A (en) 1988-01-13 1989-08-11 Mclean Hospital Corporation, The Genetic constructs containing the alzheimer brain amyloid gene
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5576184A (en) 1988-09-06 1996-11-19 Xoma Corporation Production of chimeric mouse-human antibodies with specificity to human tumor antigens
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5227159A (en) 1989-01-31 1993-07-13 Miller Richard A Anti-idiotype antibodies reactive with shared idiotopes expressed by B cell lymphomas and autoantibodies
US5262332A (en) 1989-04-05 1993-11-16 Brigham And Women's Hospital Diagnostic method for Alzheimer's disease: examination of non-neural tissue
AU5439790A (en) 1989-04-14 1990-11-16 Research Foundation For Mental Hygiene, Inc. Cerebrovascular amyloid protein-specific monoclonal antibody sv17-6e10
WO1990012870A1 (en) 1989-04-14 1990-11-01 Research Foundation For Mental Hygiene, Inc. Monoclonal antibody to amyloid peptide
WO1991001059A1 (de) * 1989-07-10 1991-01-24 Siemens Aktiengesellschaft Leiterwicklungsanordnung für eine elektrische grossmaschine
JP2625253B2 (ja) 1989-12-20 1997-07-02 オートイミューン インク 吸入投与形態をとる自己免疫疾患および／または予防用薬剤
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
ATE157257T1 (de) 1990-03-02 1997-09-15 Autoimmune Inc Verstärkung der unterdrückungsregulation von autoimmunkrankheiten durch orale oder enterale verabreichung von autoantigenen
EP0527823A1 (en) 1990-04-24 1993-02-24 The Regents Of The University Of California Purification, detection and methods of use of protease nexin-2
US5753624A (en) 1990-04-27 1998-05-19 Milkhaus Laboratory, Inc. Materials and methods for treatment of plaquing disease
GB9009548D0 (en) 1990-04-27 1990-06-20 Celltech Ltd Chimeric antibody and method
EP0526511B1 (en) 1990-04-27 1997-05-28 MCMICHAEL, John Method and composition for treatment of central nervous systems disease states associated with abnormal amyloid beta protein
AU646877B2 (en) 1990-06-15 1994-03-10 Scios Nova Inc. Transgenic non-human mammal displaying the amyloid-forming pathology of alzheimer's disease
US5780587A (en) 1990-08-24 1998-07-14 President And Fellows Of Harvard College Compounds and methods for inhibiting β-protein filament formation and neurotoxicity
US6506728B2 (en) 1990-09-25 2003-01-14 Genentech, Inc. Methods using a novel neurotrophic factor, NT-4
CA2092823A1 (en) 1990-09-28 1992-03-29 Barry D. Greenberg Transgenic animals with alzheimer's amyloid precursor gene
WO1992006708A1 (en) 1990-10-15 1992-04-30 Brigham And Women's Hospital Treatment of autoimmune diseases by oral administration of autoantigens
ATE447016T1 (de) 1991-01-21 2009-11-15 Elan Pharm Inc Prüfung und modell für alzheimers-krankheit
US5192753A (en) 1991-04-23 1993-03-09 Mcgeer Patrick L Anti-rheumatoid arthritic drugs in the treatment of dementia
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
LU91067I2 (fr) 1991-06-14 2004-04-02 Genentech Inc Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines
US5672805A (en) 1991-07-18 1997-09-30 The Regents Of The University Of California Transgenic mice expressing the neurotoxic C-terminus of β-amyloid precursor protein
US5434050A (en) 1991-08-13 1995-07-18 Regents Of The University Of Minnesota Labelled β-amyloid peptide and methods of screening for Alzheimer's disease
US5837268A (en) 1991-10-16 1998-11-17 University Of Saskatchewan GnRH-leukotoxin chimeras
JPH07506720A (ja) 1992-01-07 1995-07-27 アテナ　ニューロサイエンシーズ，　インコーポレイテッド アルツハイマー病のトランスジェニック動物モデル
US5679348A (en) 1992-02-03 1997-10-21 Cedars-Sinai Medical Center Immunotherapy for recurrent HSV infections
EP1958646A1 (en) 1992-02-11 2008-08-20 Henry M. Jackson Foundation For The Advancement Of Military Medicine Dual carrier immunogenic construct
CA2117492C (en) 1992-02-28 2009-04-07 Howard L. Weiner Bystander suppression of autoimmune diseases
US5714350A (en) * 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5441870A (en) 1992-04-15 1995-08-15 Athena Neurosciences, Inc. Methods for monitoring cellular processing of β-amyloid precursor protein
US5604102A (en) 1992-04-15 1997-02-18 Athena Neurosciences, Inc. Methods of screening for β-amyloid peptide production inhibitors
US5851787A (en) 1992-04-20 1998-12-22 The General Hospital Corporation Nucleic acid encoding amyloid precursor-like protein and uses thereof
CA2118508A1 (en) 1992-04-24 1993-11-11 Elizabeth S. Ward Recombinant production of immunoglobulin-like domains in prokaryotic cells
GB9209118D0 (en) 1992-04-28 1992-06-10 Sb 120 Amsterdam Bv Vaccine compositions
DE69327534T2 (de) * 1992-06-18 2000-06-08 The President And Fellows Of Harvard College, Cambridge Impfstoffe gegen diphtherietoxin
PT761231E (pt) 1992-06-25 2000-06-30 Smithkline Beecham Biolog Composicao de vacina contendo adjuvantes
US5837672A (en) 1992-07-10 1998-11-17 Athena Neurosciences, Inc. Methods and compositions for the detection of soluble β-amyloid peptide
US6610493B1 (en) * 1993-06-17 2003-08-26 Brigham And Women's Hospital Screening compounds for the ability to alter the production of amyloid-β peptide
US5766846A (en) 1992-07-10 1998-06-16 Athena Neurosciences Methods of screening for compounds which inhibit soluble β-amyloid peptide production
WO1994001772A1 (en) 1992-07-13 1994-01-20 The Children's Medical Center Corporation SCREEN FOR ALZHEIMER'S DISEASE THERAPEUTICS BASED ON β-AMYLOID PRODUCTION
WO1994003615A1 (en) 1992-07-31 1994-02-17 Medeva Holdings B.V. Expression of recombinant fusion proteins in attenuated bacteria
NZ255256A (en) 1992-08-27 1997-02-24 Deakin Res Ltd Synthetic peptide antigen analogues with retro, inverso or retro-inverso modification, their use and antibodies against them
US5958883A (en) 1992-09-23 1999-09-28 Board Of Regents Of The University Of Washington Office Of Technology Animal models of human amyloidoses
AU5358494A (en) 1992-10-13 1994-05-09 Duke University Method of inhibiting binding of amyloid precursor protein to beta-amyloid protein
US5605811A (en) 1992-10-26 1997-02-25 Athena Neurosciences, Inc. Methods and compositions for monitoring cellular processing of beta-amyloid precursor protein
DK1298436T3 (da) 1992-10-26 2010-10-25 Elan Pharm Inc Fremgangsmåde til identificering af inhibitorforbindelser for frisætning af beta-amyloidpeptid (BAP)
US6210671B1 (en) * 1992-12-01 2001-04-03 Protein Design Labs, Inc. Humanized antibodies reactive with L-selectin
US5955317A (en) 1993-01-25 1999-09-21 Takeda Chemical Industries, Ltd. Antibodies to β-amyloids or their derivatives and use thereof
EP0683234B2 (en) 1993-01-25 2007-06-06 Takeda Chemical Industries, Ltd. Antibody against beta-amyloid or their derivative and use thereof
US5358708A (en) 1993-01-29 1994-10-25 Schering Corporation Stabilization of protein formulations
CA2115811A1 (en) 1993-02-17 1994-08-18 Claus Krebber A method for in vivo selection of ligand-binding proteins
DE69435075T2 (de) * 1993-03-17 2009-02-19 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Immunogene chimäre umfassend nucleinsäuresequenzen, die signalsequenzpeptide des endoplasmatischen reticulums und mindestens ein anderes peptid codieren, deren verwendung in impfstoffen und zur behandlung von krankheiten
US5776468A (en) 1993-03-23 1998-07-07 Smithkline Beecham Biologicals (S.A.) Vaccine compositions containing 3-0 deacylated monophosphoryl lipid A
IT1270939B (it) 1993-05-11 1997-05-26 Angeletti P Ist Richerche Bio Procedimento per la preparazione di immunogeni e reagenti diagnostici,e immunogeni e reagenti diagnostici cosi' ottenibili.
WO1994028412A1 (en) 1993-05-28 1994-12-08 The Miriam Hospital Composition and method for in vivo imaging of amyloid deposits
US5464823A (en) 1993-07-20 1995-11-07 The Regents Of The University Of California Mammalian antibiotic peptides
ATE215124T1 (de) 1993-07-30 2002-04-15 Medeva Holdings Bv Rekombinante tetc-fusionsprotein enthaltene impfstoffzusammensetzungen
EP0664814A1 (en) 1993-08-18 1995-08-02 MorphoSys AG Lipopolysaccharide-binding and neutralizing peptides
AU705889B2 (en) 1993-08-26 1999-06-03 Regents Of The University Of California, The Method, compositions and devices for administration of naked polynucleotides which encode antigens and immunostimulatory peptides
AU707083B2 (en) 1993-08-26 1999-07-01 Bavarian Nordic Inc. Inducing antibody response against self-proteins with the aid of foreign T-cell epitopes
WO1995006407A1 (en) 1993-08-30 1995-03-09 The Regents Of The University Of California Novel component of amyloid in alzheimer's disease and methods for use of same
NZ274338A (en) 1993-09-07 1998-02-26 Smithkline Beecham Corp Chimeric and humanised il-4 monoclonal antibodies and their use
US5652334A (en) 1993-09-08 1997-07-29 City Of Hope Method for design of substances that enhance memory and improve the quality of life
US5385887A (en) * 1993-09-10 1995-01-31 Genetics Institute, Inc. Formulations for delivery of osteogenic proteins
EP0735893B1 (en) 1993-09-14 2008-11-26 Pharmexa Inc. Pan dr-binding peptides for enhancement of the immune response
US5470951A (en) 1993-09-29 1995-11-28 City Of Hope Peptides for antagonizing the effects of amyloid βprotein
US5858981A (en) * 1993-09-30 1999-01-12 University Of Pennsylvania Method of inhibiting phagocytosis
AU683703B2 (en) 1993-10-20 1997-11-20 Duke University Method of binding material to the beta-amyloid peptide
CA2172507C (en) 1993-10-22 2008-12-02 Jeffrey L. Cleland Methods and compositions for microencapsulation of antigens for use as vaccines
US5744368A (en) 1993-11-04 1998-04-28 Research Foundation Of State University Of New York Methods for the detection of soluble amyloid β-protein (βAP) or soluble transthyretin (TTR)
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5434170A (en) 1993-12-23 1995-07-18 Andrulis Pharmaceuticals Corp. Method for treating neurocognitive disorders
AU1909695A (en) 1994-01-27 1995-08-15 Regents Of The University Of Minnesota Transgenic non-human mammals with progressive neurologic disease
US5877399A (en) 1994-01-27 1999-03-02 Johns Hopkins University Transgenic mice expressing APP-Swedish mutation develop progressive neurologic disease
EP0802797A1 (en) 1994-02-03 1997-10-29 The Picower Institute For Medical Research Compositions and methods for advanced glycosylation endproduct-mediated modulation of amyloidosis
AUPM411994A0 (en) 1994-02-25 1994-03-24 Deakin Research Limited Epitopes
US5795954A (en) 1994-03-04 1998-08-18 Genentech, Inc. Factor VIIa inhibitors from Kunitz domain proteins
US6270757B1 (en) * 1994-04-21 2001-08-07 Genetics Institute, Inc. Formulations for IL-11
US6372716B1 (en) * 1994-04-26 2002-04-16 Genetics Institute, Inc. Formulations for factor IX
DE69521700T2 (de) 1994-05-25 2001-10-25 John Mcmichael Mittel und methoden zur behandlung von plaque-krankheiten
US5622701A (en) 1994-06-14 1997-04-22 Protein Design Labs, Inc. Cross-reacting monoclonal antibodies specific for E- and P-selectin
US6417178B1 (en) 1994-07-19 2002-07-09 University Of Pittsburgh Amyloid binding nitrogen-linked compounds for the antemortem diagnosis of alzheimer's disease, in vivo imaging and prevention of amyloid deposits
US6114133A (en) 1994-11-14 2000-09-05 Elan Pharmaceuticals, Inc. Methods for aiding in the diagnosis of Alzheimer's disease by measuring amyloid-β peptide (x-≧41)
US5589154A (en) 1994-11-22 1996-12-31 Rutgers, The State University Of New Jersey Methods for the prevention or treatment of vascular hemorrhaging and Alzheimer's disease
US5688651A (en) 1994-12-16 1997-11-18 Ramot University Authority For Applied Research And Development Ltd. Prevention of protein aggregation
ATE216590T1 (de) * 1995-02-06 2002-05-15 Genetics Inst Arzneimittelformulierungen für il-12
US5786180A (en) 1995-02-14 1998-07-28 Bayer Corporation Monoclonal antibody 369.2B specific for β A4 peptide
US5624937A (en) * 1995-03-02 1997-04-29 Eli Lilly And Company Chemical compounds as inhibitors of amyloid beta protein production
US5817626A (en) 1995-03-14 1998-10-06 Praecis Pharmaceuticals Incorporated Modulators of beta-amyloid peptide aggregation
US5854215A (en) 1995-03-14 1998-12-29 Praecis Pharmaceuticals Incorporated Modulators of β-amyloid peptide aggregation
US6303567B1 (en) 1995-03-14 2001-10-16 Praecis Pharmaceuticals, Inc . Modulators of β-amyloid peptide aggregation comprising D-amino acids
DE69621607T2 (de) 1995-03-14 2003-01-02 Praecis Pharmaceuticals Inc., Waltham VERBINDUNGEN MIT AGGREGATIONS-MODULIERENDEN WIRKUNG AUF DAS AMYLOiD PROTEIN
US6121022A (en) * 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5869046A (en) * 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
CA2222055A1 (en) 1995-05-23 1996-11-28 Morphosys Gesellschaft Fur Proteinoptimierung Mbh Multimeric proteins
AU6113896A (en) 1995-06-05 1996-12-24 Brigham And Women's Hospital Use of oral tolerance to suppress both th1 and th2 immune re sponses and to suppress antibody production
PT750907E (pt) 1995-06-30 2002-08-30 American Cyanamid Co Formulacoes de vacinas estaveis para administracao parenterica metodo para a sua utilizacao e processo para a sua preparacao
ATE305039T1 (de) 1995-07-07 2005-10-15 Darwin Molecular Corp Auf chromosom 1 lokalisiertes gen dessen genprodukt mit der alzheimerschen krankheit assoziiert ist.
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
JP4436457B2 (ja) 1995-08-18 2010-03-24 モルフォシス アイピー ゲーエムベーハー 蛋白質／（ポリ）ペプチドライブラリー
WO1997006809A1 (en) 1995-08-21 1997-02-27 Cytrx Corporation Compositions and methods for growth promotion
EP1416280A3 (en) 1995-09-14 2005-08-10 The Regents of the University of California Antibodies specific for native PrPsc
US5731284A (en) * 1995-09-28 1998-03-24 Amgen Inc. Method for treating Alzheimer's disease using glial line-derived neurotrophic factor (GDNF) protein product
US5985242A (en) 1995-10-27 1999-11-16 Praecis Pharmaceuticals, Inc. Modulators of β-amyloid peptide aggregation comprising D-amino acids
US5750361A (en) 1995-11-02 1998-05-12 The Regents Of The University Of California Formation and use of prion protein (PRP) complexes
CA2235226A1 (en) 1995-11-10 1997-05-15 Elan Corporation, Plc Peptides which enhance transport across tissues and methods of identifying and using the same
AU1072897A (en) 1995-12-12 1997-07-03 Karolinska Innovations Ab Peptide binding the klvff-sequence of amyloid beta
US5770700A (en) * 1996-01-25 1998-06-23 Genetics Institute, Inc. Liquid factor IX formulations
JP2000505306A (ja) 1996-02-26 2000-05-09 モルフォシス・アクチェンゲゼルシャフト ２つまたはそれ以上の相互作用性（ポリ）ペプチドをコードする核酸配列の新規同定方法
US6150091A (en) 1996-03-06 2000-11-21 Baylor College Of Medicine Direct molecular diagnosis of Friedreich ataxia
US6284533B1 (en) 1996-05-01 2001-09-04 Avant Immunotherapeutics, Inc. Plasmid-based vaccine for treating atherosclerosis
JP2000516452A (ja) 1996-07-16 2000-12-12 プリュックテュン，アンドレアス 可溶性が増大した免疫グロブリンスーパーファミリードメインおよびフラグメント
CA2183901A1 (en) 1996-08-22 1998-02-23 Johanna E. Bergmann Targets for therapy and diagnosis of alzheimer's disease and down syndrome in humans
PT929574E (pt) 1996-08-27 2005-11-30 Praecis Pharm Inc Moduladores da agregacao de peptidos beta-amiloides compreendendo d-aminoacidos
US6057367A (en) 1996-08-30 2000-05-02 Duke University Manipulating nitrosative stress to kill pathologic microbes, pathologic helminths and pathologically proliferating cells or to upregulate nitrosative stress defenses
US6797495B2 (en) 1996-11-05 2004-09-28 The Regents Of The University Of California Somatic cells with ablated PrP gene and methods of use
US6022859A (en) 1996-11-15 2000-02-08 Wisconsin Alumni Research Foundation Inhibitors of β-amyloid toxicity
AU5508798A (en) 1996-11-19 1998-06-10 Trustees Of The University Of Pennsylvania, The Diagnostic and therapeutic reagents for alzheimer's disease
US6962984B2 (en) 1996-12-05 2005-11-08 Nihon University IgA nephropathy-related DNA
US6218506B1 (en) 1997-02-05 2001-04-17 Northwestern University Amyloid β protein (globular assembly and uses thereof)
US20030068316A1 (en) 1997-02-05 2003-04-10 Klein William L. Anti-ADDL antibodies and uses thereof
US6277375B1 (en) * 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US5798102A (en) * 1997-03-04 1998-08-25 Milkhaus Laboratory, Inc. Treatment of cardiomyopathy
ATE402717T1 (de) 1997-04-09 2008-08-15 Intellect Neurosciences Inc Für die termini des beta-amyloids spezifische, rekombinante antikörper, dafür kodierende dna und verfahren zu ihrer verwendung
US20020086847A1 (en) 1997-04-09 2002-07-04 Mindset Biopharmaceuticals (Usa) Recombinant antibodies specific for beta-amyloid ends, DNA encoding and methods of use thereof
US8173127B2 (en) 1997-04-09 2012-05-08 Intellect Neurosciences, Inc. Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof
US6787319B2 (en) 1997-04-16 2004-09-07 American Home Products Corp. β-amyloid peptide-binding proteins and polynucleotides encoding the same
CA2301575C (en) * 1997-05-20 2003-12-23 Ottawa Civic Hospital Loeb Research Institute Vectors and methods for immunization or therapeutic protocols
DE69810481T2 (de) 1997-06-13 2003-09-25 Genentech Inc., San Francisco Stabilisierte antikörperformulierung
AU8269898A (en) 1997-06-27 1999-01-19 Regents Of The University Of California, The Drug targeting of a peptide radiopharmaceutical through the primate blood-brain barrier in vivo with a monoclonal antibody to the human insulin receptor
IT1293511B1 (it) 1997-07-30 1999-03-01 Gentili Ist Spa Anticorpi monoclonali catalitici ad attivita' proteasica per la lisi selettiva della componente proteica di placche e aggregati correlati
EP1001987B1 (en) 1997-08-01 2010-12-15 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Composition and method for the detection of diseases associated with amyloid-like fibril or protein aggregate formation
JP2002501721A (ja) 1997-08-01 2002-01-22 モルフォシス・アクチェンゲゼルシャフト 多量体（ポリ）ペプチドコンプレックスのメンバーをコードする核酸配列を同定するための新規方法およびファージ
EP2050465B1 (en) 1997-08-29 2014-06-11 Antigenics Inc. Compositions comprising the adjuvant QS-21 and polysorbate or cyclodextrin as excipient
US6175057B1 (en) * 1997-10-08 2001-01-16 The Regents Of The University Of California Transgenic mouse model of alzheimer's disease and cerebral amyloid angiopathy
EP0921189B1 (en) * 1997-11-14 2005-01-12 Sankyo Company Limited Transgenic animal allergy models and methods for their use
US6905686B1 (en) * 1997-12-02 2005-06-14 Neuralab Limited Active immunization for treatment of alzheimer's disease
US6761888B1 (en) 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US6787523B1 (en) * 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6750324B1 (en) * 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
US6710226B1 (en) * 1997-12-02 2004-03-23 Neuralab Limited Transgenic mouse assay to determine the effect of Aβ antibodies and Aβ Fragments on alzheimer's disease characteristics
US6913745B1 (en) * 1997-12-02 2005-07-05 Neuralab Limited Passive immunization of Alzheimer's disease
US20080050367A1 (en) * 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US7790856B2 (en) * 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US7179892B2 (en) * 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
US6923964B1 (en) * 1997-12-02 2005-08-02 Neuralab Limited Active immunization of AScr for prion disorders
NZ504711A (en) 1997-12-03 2002-02-01 Fujisawa Pharmaceutical Co Soft-pellet drug and process for the preparation thereof
JP2002511385A (ja) 1997-12-03 2002-04-16 ニューララブ リミテッド アルツハイマー病におけるβ−アミロイド関連変化を抑制する方法
FR2777015B3 (fr) 1998-02-23 2000-09-15 Financ De Biotechnologie Procede et moyens pour l'obtention de modeles cellulaires et animaux de maladies neurodegeneratives
US6194551B1 (en) * 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6528624B1 (en) * 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
US20050059591A1 (en) * 1998-04-07 2005-03-17 Neuralab Limited Prevention and treatment of amyloidogenic disease
US20050059802A1 (en) * 1998-04-07 2005-03-17 Neuralab Ltd Prevention and treatment of amyloidogenic disease
ES2230848T3 (es) * 1998-04-28 2005-05-01 Smithkline Beecham Corporation Anticuerpos monoclonales con inmunogenicidad reducida.
NO314086B1 (no) 1998-05-08 2003-01-27 Gemvax As Peptider og farmasöytiske sammensetninger inneholdende disse, nukleinsyresekvenser som koder for slike peptider, plasmider og virusvektoreromfattende slike DNA-sekvenser samt anvendelse av disse for fremstilling avfarmasöytiske preparater til
WO1999060021A2 (en) 1998-05-19 1999-11-25 Yeda Research And Development Co. Ltd. Use of activated t cells, nervous system-specific antigens for treating disorders of the nevrous system
ATE465178T1 (de) 1998-05-21 2010-05-15 Univ Tennessee Res Foundation Methoden zur amyloidentfernung mit anti-amyloid- antikörper
US20030147882A1 (en) 1998-05-21 2003-08-07 Alan Solomon Methods for amyloid removal using anti-amyloid antibodies
US6727349B1 (en) 1998-07-23 2004-04-27 Millennium Pharmaceuticals, Inc. Recombinant anti-CCR2 antibodies and methods of use therefor
DE69918146T2 (de) 1998-10-05 2005-07-07 Pharmexa A/S Verfahren zur therapeutischen impfung
WO2000023082A1 (en) 1998-10-19 2000-04-27 Yeda Research And Development Co. Ltd. Treatment of systemic lupus erythematosus by down-regulating the autoimmune response to autoantigens
GB2348203B (en) 1998-11-04 2002-06-19 Imp College Innovations Ltd Solube beta-forms of prion proteins, methods of preparation and use
AU778270C (en) 1999-01-19 2005-07-21 Pharmacia & Upjohn Company Gamma-irradiation sterilized polyethylene packaging
CA2361124A1 (en) 1999-01-22 2000-07-27 Matthew John During Vaccine-mediated treatment of neurological disorders
AU4529800A (en) 1999-05-05 2000-11-21 Neurochem, Inc. Stereoselective antifibrillogenic peptides and peptidomimetics thereof
US6787637B1 (en) 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
UA81216C2 (en) 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
PE20010212A1 (es) 1999-06-01 2001-02-22 Neuralab Ltd Composiciones del peptido a-beta y procesos para producir las mismas
AU780474B2 (en) 1999-06-16 2005-03-24 Boston Biomedical Research Institute Incorporated Immunological control of beta-amyloid levels in vivo
BR0012429A (pt) 1999-07-15 2002-09-17 Genetics Inst Fórmulações para il-11
ATE283285T1 (de) 1999-08-04 2004-12-15 Univ Southern California Globularer aufbau vom amyloid-beta- protein und deren verwendungen
WO2001018169A2 (en) * 1999-09-03 2001-03-15 Ramot University Authority For Applied Research & Industrial Development Ltd. Agents and compositions and methods for diagnostic and/or treating or preventing plaque forming diseases
US6294171B2 (en) 1999-09-14 2001-09-25 Milkhaus Laboratory, Inc. Methods for treating disease states comprising administration of low levels of antibodies
CA2388559A1 (en) 1999-11-29 2001-06-07 Neurochem Inc. Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases
US20020094335A1 (en) 1999-11-29 2002-07-18 Robert Chalifour Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases
ES2275570T3 (es) 1999-12-08 2007-06-16 Intellect Neurosciences, Inc. Peptidos amiloides beta quimericos.
US6399314B1 (en) 1999-12-29 2002-06-04 American Cyanamid Company Methods of detection of amyloidogenic proteins
ATE306933T1 (de) 2000-02-21 2005-11-15 Pharmexa As Verfahren zur herabregulierung von amyloid
AU783144B2 (en) 2000-02-21 2005-09-29 H. Lundbeck A/S Novel method for down-regulation of amyloid
KR100767146B1 (ko) * 2000-02-24 2007-10-15 워싱톤 유니버시티 Ａβ 펩티드를 격리시키는 인간화 항체
US6992984B1 (en) * 2000-03-07 2006-01-31 Lucent Technologies Inc. Credit-based adaptive flow control for multi-stage multi-dimensional switching architecture
CA2404237C (en) 2000-04-05 2010-01-26 University Of Tennessee Research Corporation Methods of investigating, diagnosing, and treating amyloidosis
PT1284998E (pt) 2000-05-22 2005-06-30 Univ New York Eptideos imunogenicos sinteticos mas nao-amiloidogenicos homologos a beta-amiloides, destinados a induzir uma reaccao imunitaria contra os beta-amiloides e os depositos amiloides
EP1309341A2 (en) 2000-07-07 2003-05-14 Lars Lannfelt Prevention and treatment of alzheimer's disease
US20020009445A1 (en) 2000-07-12 2002-01-24 Yansheng Du Human beta-amyloid antibody and use thereof for treatment of alzheimer's disease
EP1172378A1 (en) 2000-07-12 2002-01-16 Richard Dr. Dodel Human beta-amyloid antibody and use thereof for treatment of alzheimer's disease
US20030092145A1 (en) * 2000-08-24 2003-05-15 Vic Jira Viral vaccine composition, process, and methods of use
US7067133B2 (en) 2000-09-06 2006-06-27 Aventis Pharma S.A. Methods and compositions for diseases associated with amyloidosis
IT1319277B1 (it) 2000-10-24 2003-09-26 Chiesi Farma Spa Proteine di fusione utili per il trattamento di immunizzazione dellamalattia di alzheimer.
IL139308A0 (en) 2000-10-26 2001-11-25 Marikovsky Moshe Peptides from amyloid precursor protein which inhibit tumor growth and metastasis
ES2283463T3 (es) 2000-11-27 2007-11-01 Praecis Pharmaceuticals Incorporated Agentes terapeuticpos y metodos de uso de los mismos para tratar una enfermedad amiloidogenica.
TWI255272B (en) * 2000-12-06 2006-05-21 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
AU2002246734A1 (en) 2000-12-27 2002-08-12 University Of Texas Health Science Center Houston Prion isomers, methods of making, methods of using, and compositions and products comprising prion isomers
WO2002059621A2 (en) 2001-01-24 2002-08-01 Bayer Corporation Regulation of transthyretin to treat obesity
DE60121729T2 (de) 2001-04-19 2007-11-29 Dr. Hermann Schätzl Prion Proteindimere für Impfungen
AU2002257162A1 (en) 2001-04-30 2002-11-11 Eli Lilly And Company Humanized antibodies
EP2165714B1 (en) 2001-04-30 2013-10-23 Eli Lilly And Company Humanized antibodies recognizing the beta-amyloid peptide
US6906169B2 (en) 2001-05-25 2005-06-14 United Biomedical, Inc. Immunogenic peptide composition comprising measles virus Fprotein Thelper cell epitope (MUFThl-16) and N-terminus of β-amyloid peptide
GB0113179D0 (en) 2001-05-31 2001-07-25 Novartis Ag Organic compounds
US20020197258A1 (en) 2001-06-22 2002-12-26 Ghanbari Hossein A. Compositions and methods for preventing protein aggregation in neurodegenerative diseases
EP1409018B1 (en) 2001-07-25 2010-01-06 Facet Biotech Corporation Stable lyophilized pharmaceutical formulation the igg antibody daclizumab
US20030135035A1 (en) * 2001-08-09 2003-07-17 Mark Shannon Human ZZAP1 protein
AU2002324468A1 (en) 2001-08-17 2003-03-03 Eli Lilly And Company Rapid improvement of cognition in conditions related to abeta
WO2003016466A2 (en) 2001-08-17 2003-02-27 Eli Lilly And Company ANTI-Aβ ANTIBODIES
WO2003016467A2 (en) 2001-08-17 2003-02-27 Eli Lilly And Company Use of antibodies having high affinity for soluble ass to treat conditions and diseases related to ass
US20030082191A1 (en) 2001-08-29 2003-05-01 Poduslo Joseph F. Treatment for central nervous system disorders
US7781413B2 (en) * 2001-10-31 2010-08-24 Board Of Regents, The University Of Texas System SEMA3B inhibits tumor growth and induces apoptosis in cancer cells
ATE556591T1 (de) 2001-11-08 2012-05-15 Abbott Biotherapeutics Corp Stabile pharmazeutische flüssigformulierung von igg-antikörpern
WO2003045128A2 (en) 2001-11-21 2003-06-05 New York University SYNTHETIC IMMUNOGENIC BUT NON-DEPOSIT-FORMING POLYPEPTIDES AND PEPTIDES HOMOLOGOUS TO AMYLOID β, PRION PROTEIN, AMYLIN, α-SYNUCLEIN, OR POLYGLUTAMINE REPEATS FOR INDUCTION OF AN IMMUNE RESPONSE THERETO
AU2002366355A1 (en) 2001-12-17 2003-06-30 New York State Office Of Mental Health SEQUESTRATION OF ABeta IN THE PERIPHERY IN THE ABSENCE OF IMMUNOMODULATING AGENT AS A THERAPEUTIC APPROACH FOR THE TREATMENT OR PREVENTION OF BETA-AMYLOID RELATED DISEASES
AR038568A1 (es) * 2002-02-20 2005-01-19 Hoffmann La Roche Anticuerpos anti-a beta y su uso
JP2005526501A (ja) 2002-02-21 2005-09-08 デューク・ユニヴァーシティ 自己免疫疾患用の試薬および治療方法
MY139983A (en) * 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
CA2487528A1 (en) 2002-07-24 2004-02-12 Innogenetics N.V. Prevention, treatment and diagnosis of diseases associated with beta-amyloid formation and/or aggregation
EP1545582A4 (en) 2002-10-01 2008-09-17 Univ Northwestern DIFFUSIBLE DERIVATIVES DERIVED FROM AMYLOID BETA (ADDL), ADDL SUBSTITUTE, ADDL BINDING MOLECULES, AND USES THEREOF
FR2846667B1 (fr) 2002-11-06 2004-12-31 Pasteur Institut Fragments variables d'anticorps de camelides a chaine unique diriges contre le peptide beta-amyloide 1-42 et leurs applications pour le diagnostic et le traitement des maladies neuroagregatives
WO2004055164A2 (en) 2002-12-13 2004-07-01 Abgenix, Inc. System and method for stabilizing antibodies with histidine
US6787129B1 (en) * 2003-01-13 2004-09-07 Zenitech Llc Castor polyester as gloss agents in anionic systems
WO2004069182A2 (en) 2003-02-01 2004-08-19 Neuralab Limited Active immunization to generate antibodies to soluble a-beta
DE602004027348D1 (de) 2003-02-10 2010-07-08 Applied Molecular Evolution Abeta-bindende moleküle
JP4869064B2 (ja) 2003-04-04 2012-02-01 ジェネンテック， インコーポレイテッド 高濃度抗体及びタンパク質製剤
EP1480041A1 (en) 2003-05-22 2004-11-24 Innogenetics N.V. Method for the prediction, diagnosis and differential diagnosis of Alzheimer's disease
TWI306458B (en) 2003-05-30 2009-02-21 Elan Pharma Int Ltd Humanized antibodies that recognize beta amyloid peptide
WO2005014041A2 (en) 2003-07-24 2005-02-17 Novartis Ag Use of an amyloid beta dna vaccine for the treatment and/or prevention of amyloid diseases
EP1670827A2 (en) 2003-09-05 2006-06-21 Eli Lilly And Company Anti-ghrelin antibodies
EA009559B1 (ru) * 2003-12-17 2008-02-28 Элан Фармасьютикелз, Инк. КОНЪЮГАТЫ Aβ ИММУНОГЕННЫХ ПЕПТИДНЫХ НОСИТЕЛЕЙ И СПОСОБЫ ИХ ПОЛУЧЕНИЯ
US20070134762A1 (en) 2003-12-17 2007-06-14 Arumugham Rasappa G Immunogenic peptide carrier conjugates and methods of producing same
EP1828251B1 (en) * 2004-10-05 2012-09-26 Janssen Alzheimer Immunotherapy Methods and compositions for improving recombinant protein production
US20060160161A1 (en) * 2004-10-26 2006-07-20 Elan Pharmaceuticals, Inc. Methods for assessing antibodies to neurodegenerative disease-associated antigens
CA2590337C (en) 2004-12-15 2017-07-11 Neuralab Limited Humanized amyloid beta antibodies for use in improving cognition
WO2006066118A2 (en) * 2004-12-15 2006-06-22 Neuralab Limited Contextual fear test for predicting efficacy of alzheimer immunotherapeutic treatment
AR051800A1 (es) 2004-12-15 2007-02-07 Wyeth Corp Anticuerpos a beta usados en mejorar la cognicion
US7625560B2 (en) * 2004-12-15 2009-12-01 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US20060240486A1 (en) 2004-12-15 2006-10-26 Johnson-Wood Kelly L Immunoprecipitation-based assay for predicting in vivo efficacy of beta-amyloid antibodies
GT200600031A (es) 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
CA2595380A1 (en) 2005-01-28 2006-08-03 Wyeth Stabilized liquid polypeptide formulations
KR101247836B1 (ko) * 2005-06-17 2013-03-28 와이어쓰 엘엘씨 항 ａ 베타 항체의 정제 방법

Also Published As

Publication number Publication date
WO2004108895A3 (en) 2005-07-28
JP2007536895A (ja) 2007-12-20
AR044580A1 (es) 2005-09-21
ES2382547T3 (es) 2012-06-11
TW200911830A (en) 2009-03-16
CO5660296A2 (es) 2006-07-31
UY28337A1 (es) 2004-12-31
HK1088617A1 (en) 2006-11-10
CA2525975C (en) 2014-09-23
NO20055415L (no) 2006-02-20
NZ544324A (en) 2009-05-31
KR101152583B1 (ko) 2012-07-17
KR20060024389A (ko) 2006-03-16
ECSP056263A (es) 2006-04-19
AU2004245989B2 (en) 2011-06-16
EP1636268B1 (en) 2012-02-15
EA012407B1 (ru) 2009-10-30
US7871615B2 (en) 2011-01-18
DK1636268T3 (da) 2012-05-29
TW200510458A (en) 2005-03-16
KR101455479B1 (ko) 2014-10-28
US20050118651A1 (en) 2005-06-02
CN1798766B (zh) 2012-05-30
EP1636268A4 (en) 2007-02-21
MXPA05012718A (es) 2006-02-08
EA200501891A1 (ru) 2006-06-30
UA90846C2 (ru) 2010-06-10
MY176959A (en) 2020-08-27
AU2004245989A1 (en) 2004-12-16
JP4908203B2 (ja) 2012-04-04
IL171877A0 (en) 2006-04-10
CN1798766A (zh) 2006-07-05
EP1636268B8 (en) 2012-03-21
TWI374893B (en) 2012-10-21
EP1636268A2 (en) 2006-03-22
TWI306458B (en) 2009-02-21
NO20055415D0 (no) 2005-11-16
ZA200509585B (en) 2009-01-28
PE20050627A1 (es) 2005-08-10
IL171877A (en) 2012-05-31
ATE545656T1 (de) 2012-03-15
CA2525975A1 (en) 2004-12-16
PL1636268T3 (pl) 2012-07-31
WO2004108895A2 (en) 2004-12-16
CR8095A (es) 2007-11-23
SI1636268T1 (sl) 2012-06-29
PT1636268E (pt) 2012-05-23
KR20120060949A (ko) 2012-06-12

Similar Documents

Publication Publication Date Title
BRPI0410860A (pt) cadeias leve e pesada de imunoglobulina humanizada, imunoglobulina humanizada, anticorpo humanizado, imunoglobulina quimérica, composição farmacêutica, polipeptìdeo isolado, variante de um polipeptìdeo, molécula de ácido nucleico isolada, vetor, célula hospedeira, animal transgênico, uso da seqüência de região variável, kit para formar imagem, composição terapêutica, e, métodos para prevenir ou tratar uma doença amiloidogênica e mal de alzheimer em um paciente, para produzir um anticorpo ou fragmento do mesmo, para identificar resìduos passiveis de substituição, para formar imagem de depósitos de amilóides no cérebro de um paciente, para reduzir carga de placa em um sujeito, para reduzir carga neurìtica em um sujeito, e, para reduzir carga de peptìdeo beta amilóide e distrofia neurìtica em um mamìfero
BR0308143A (pt) cadeia leve, cadeia pesada, imunoglobulina, anticorpo humanizado. composição farmacêutica e terapêutica, polipeptìdeo e peptìdeo isolado, variante do polipeptìdeo, molécula de ácido nucleico isolada, vetor, célula hospedeira, animal transgênico, uso da seqüência de região variável apresentada como a seq id no: 2 ou seq id no. 4 e métodos de prevenir ou tratar uma doença amiloidogênica e associada com depósito amilóides de abeta no cérebro de um paciente e mal de alzheimer, de produzir um anticorpo ou fragmento do mesmo, de identificar resìduos sensìveis à substituição em uma região de estrutura variável da imunoglobulina, de produzir imagem de depósitos amilóides no cérebro de um paciente e de reduzir a carga de placa, neutìtica e de peptìdeo amilóide beta (abeta) e a distrofia neurìtica
ES2396555T3 (es) Anticuerpos que reconocen péptido beta amiloide
ES2773961T3 (es) Uso de moléculas de unión a semaforina-4D para el tratamiento de trastornos neurodegenerativos
ES2434732T3 (es) Anticuerpos para beta-amiloide humanizados para su uso en mejorar la cognición
CN101830974B (zh) 淀粉样β(1‑42)蛋白寡聚体、其衍生物及抗体、其制备方法和用途
ES2925716T3 (es) Anticuerpos anti-transtiretina
Xiao et al. Cerebral complement C1q activation in chronic Toxoplasma infection
CN104619724B (zh) 识别α-突触核蛋白的人源化抗体
ES2766257T3 (es) Métodos y composiciones para regular la homeostasis del hierro mediante la modulación de bmp-6
NO973447D0 (no) Monoklonale antistoffer som er spesifikke for forskjellige epitoper i human-gp 39, og fremgangsmåter for deres anvendelse i diagnose og terapi
TW200844110A (en) Diagnosis and treatment of alzheimer&#39;s disease and other neurodementing diseases
DK2004688T4 (da) Forbedrede selektive protofibrille antistoffer og anvendelsen deraf
BRPI0619748A8 (pt) anticorpo monoclonal, polinucleotídeo, região variável de cadeia leve, região variável de cadeia pesada, composição, mistura, métodos para produzir um anticorpo, para preparar uma composição farmacêutica ou uma mistura, de diagnóstico de uma doença ou condição associada a amilóide, para determinar o grau de carga de placa amiloidogênica em um tecido, para diagnosticar uma predisposição para uma doença ou condição, para monitorar doença residual mínima e para prever responsabilidade de um paciente, uso de um anticorpo monoclonal e/ou uma parte funcional do mesmo e/ou uma composição farmacêutica ou uma mistura, linhagem celular de hibridoma, e, kits de teste
AU2003270643A8 (en) Immunogens and corresponding antibodies specific for high molecular weight aggregation intermediates common to amyloids formed from proteins of differing sequence
JP7626416B2 (ja) 神経変性疾患または神経炎症性疾患におけるグリア細胞活性化の早期検出方法
CN107847595A (zh) 特异性针对过度磷酸化τ蛋白的抗体及其使用方法
KR20080090408A (ko) 항-Ａβ 글로불로머 항체, 이의 항원-결합 잔기, 상응하는하이브리도마, 핵산, 벡터, 숙주 세포, 당해 항체의 제조방법, 당해 항체를 포함하는 조성물, 당해 항체의 용도 및당해 항체의 사용 방법
EA200700083A1 (ru) Антитела, направленные против бета-амилоидного пептида, и способы их применения
US20200030445A1 (en) Stable formulations of humanized anti-tau antibody
TW202118782A (zh) 抗甲狀腺素運送蛋白抗體
CN110418804A (zh) 与tau特异性地结合的结合分子
US20230391859A1 (en) Anti-transthyretin antibodies and methods of use thereof
ES2582559T3 (es) Factor trófico para el tratamiento de las enfermedades degenerativas de la retina
MX2010013628A (es) Metodo para seleccionar compuestos que inhiben la neurodegeneracion.

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: WYETH (US) , ELAN PHARMA INTERNATIONAL LIMITED (IE

Free format text: TRANSFERIDO DE: NEURALAB LIMITED

B25D Requested change of name of applicant approved

Owner name: ELAN PHARMA INTERNATIONAL LIMITED (IE) , WYETH LLC

Free format text: ALTERADO DE: WYETH

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25A Requested transfer of rights approved

Owner name: WYETH LLC (US) , CRIMAGUA LIMITED (IE)

Free format text: TRANSFERIDO DE: ELAN PHARMA INTERNATIONAL LIMITED

B25A Requested transfer of rights approved

Owner name: WYETH LLC (US) , JANSSEN ALZHEIMER IMMUNOTHERAPY (

Free format text: TRANSFERIDO DE: CRIMAGUA LIMITED

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal of application maintained [chapter 11.20 patent gazette]